NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024, both dates inclusive (the “Class Period”), of the important June 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Treace Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

Core Insights - Veracyte reported quarterly earnings of $0.31 per share, exceeding the Zacks Consensus Estimate of $0.20 per share, and showing a significant improvement from a loss of $0.02 per share a year ago, resulting in an earnings surprise of 55% [1] - The company achieved revenues of $114.47 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.17% and reflecting a year-over-year increase from $96.84 million [2] - Veracyte has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Outlook - The future performance of Veracyte's stock will largely depend on management's commentary during the earnings call and the sustainability of the recent earnings surprise [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.31, with projected revenues of $122.71 million, and for the current fiscal year, the consensus EPS is $1.09 on revenues of $490.64 million [7] Industry Context - The Medical - Instruments industry, to which Veracyte belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]

Core Insights - Orthofix reported a quarterly loss of $0.08 per share, better than the Zacks Consensus Estimate of a loss of $0.17, and an improvement from a loss of $0.46 per share a year ago, indicating a 52.94% earnings surprise [1] - The company achieved revenues of $193.65 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.87% and showing a year-over-year increase from $188.61 million [2] - Orthofix shares have declined approximately 22.5% year-to-date, contrasting with the S&P 500's decline of 3.9% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.08, with projected revenues of $204 million, and for the current fiscal year, the EPS estimate is $0.62 on revenues of $823.9 million [7] - The estimate revisions trend for Orthofix is currently favorable, leading to a Zacks Rank 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6] Industry Context - The Medical - Instruments industry, to which Orthofix belongs, is currently ranked in the top 25% of over 250 Zacks industries, indicating a strong performance potential [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024, both dates inclusive (the “Class Period”), of the important June 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Treace Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024, both dates inclusive (the “Class Period”), of the important June 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Treace Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...